SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Regeneron Pharmaceuticals, Inc. (REGN) trades at a trailing P/E of 17.6, forward P/E of 16.7. Trailing earnings yield is 5.67%, forward earnings yield 6.00%. PEG 2.15. Graham Number is $547.01.
Criteria proven by this page:
- VALUE (75/100, Pass) — P/E is below market average (17.6); analyst target implies upside (+14.2%); earnings yield beats bond yields (5.67%).
- Forward P/E 16.7 (down from trailing 17.6) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 2.15 — above 2.0 suggests expensive relative to earnings growth.
- Trailing Earnings Yield 5.67% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 6.00% as earnings recover.
- Analyst consensus target $862.74 (+14.2% upside) — modest upside expected.
Overall SharesGrow Score: 83/100 with 6/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
75/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — REGN
Valuation Multiples
P/E (TTM)17.6
Forward P/E16.7
PEG Ratio2.15
Forward PEG1.79
P/B Ratio2.54
P/S Ratio5.59
EV/EBITDA13.7
Per Share Data
EPS (TTM)$43.78
Forward EPS (Est.)$45.35
Book Value / Share$303.76
Revenue / Share$139.39
FCF / Share$39.66
Yields & Fair Value
Earnings Yield5.67%
Forward Earnings Yield6.00%
Dividend Yield0.46%
Graham Number$547.01
SharesGrow IV$1,711.01 (+126.5%)
Analyst Target$862.74 (+14.2%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
47.7 |
1.24 |
9.59 |
8.78 |
- |
| 2017 |
36.4 |
1.14 |
7.09 |
7.42 |
- |
| 2018 |
17.5 |
0.20 |
4.90 |
6.39 |
- |
| 2019 |
19.4 |
-2.16 |
3.70 |
6.25 |
- |
| 2020 |
14.8 |
0.22 |
4.71 |
6.12 |
- |
| 2021 |
8.3 |
0.06 |
3.56 |
4.15 |
- |
| 2022 |
17.8 |
-0.38 |
3.41 |
6.35 |
- |
| 2023 |
23.7 |
-2.78 |
3.61 |
7.14 |
- |
| 2024 |
17.4 |
1.68 |
2.62 |
5.41 |
- |
| 2025 |
17.9 |
3.38 |
2.58 |
5.63 |
0.46% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$7.70 |
$4.86B |
$895.52M |
18.4% |
| 2017 |
$10.34 |
$5.87B |
$1.2B |
20.4% |
| 2018 |
$21.29 |
$6.71B |
$2.44B |
36.4% |
| 2019 |
$18.46 |
$7.86B |
$2.12B |
26.9% |
| 2020 |
$30.52 |
$8.5B |
$3.51B |
41.3% |
| 2021 |
$71.97 |
$16.07B |
$8.08B |
50.2% |
| 2022 |
$38.22 |
$12.17B |
$4.34B |
35.6% |
| 2023 |
$34.77 |
$13.12B |
$3.95B |
30.1% |
| 2024 |
$38.34 |
$14.2B |
$4.41B |
31.1% |
| 2025 |
$41.48 |
$14.34B |
$4.5B |
31.4% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$45.38 |
$33.43 – $51.52 |
$15.7B |
$14.74B – $16.36B |
16 |
| 2027 |
$52.94 |
$29.88 – $66.84 |
$17.32B |
$16.14B – $19.07B |
8 |
| 2028 |
$60.83 |
$49.47 – $73.09 |
$18.7B |
$18.66B – $18.73B |
8 |
| 2029 |
$67.38 |
$60.61 – $74.35 |
$20.18B |
$18.62B – $21.78B |
6 |
| 2030 |
$71.97 |
$64.73 – $79.42 |
$21.24B |
$19.59B – $22.93B |
6 |
